PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-22.30%
Negative net income growth while RVPH stands at 5.90%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
24.17%
D&A growth of 24.17% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
100.00%
Deferred tax of 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-9.33%
Both cut yoy SBC, with RVPH at -56.99%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-80.33%
Negative yoy working capital usage while RVPH is 125.07%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-46.04%
Negative yoy AP while RVPH is 101.70%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-249.09%
Negative yoy usage while RVPH is 159.63%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-101.42%
Negative yoy while RVPH is 81.82%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-72.30%
Negative yoy CFO while RVPH is 38.83%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-455.28%
Negative yoy CapEx while RVPH is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
-427.62%
We reduce yoy invests while RVPH stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
53916.27%
Stock issuance far above RVPH's 4129.39%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.